corner
Healthy Skepticism
Join us to help reduce harm from misleading health information.
Increase font size   Decrease font size   Print-friendly view   Print
Register Log in

Healthy Skepticism Library

Items published during the years 1980 to 1989

There are 1082 items in the Healthy Skepticism Library that were published during the years 1980 to 1989.

Page 2 of 11 pages  < 1 2 3 4 >  Last ›

HSL2064
Schwartz RK, Soumerai SB, Avorn J.
Physician motivations for nonscientific drug prescribing.
Soc Sci Med 1989; 28:(6):577-82

HSL2107
Grice HP.
Studies in the Way of Words
Cambridge: Harvard University Press 1989
http://www.hup.harvard.edu/catalog/GRISTU.html

HSL3655
Further proposals on medicines
Lancet 1989; 2:752-753

HSL3656
Ginkgo biloba extract: over 5 million prescriptions a year
Lancet 1989; 2:1513-1514

HSL3657
MaLAM’s open letter to industry
Scrip 1989; (1457):23

HSL3658
Misuse of antidiarrhoeal medicines
Lancet 1989; 2:995

HSL3659
Abate MA, Jacknowitz AI, Shumway JM.
Information sources utilized by private practice and university physicians
Drug Information Journal 1989; 23:304-319

HSL3660
Adams DG.
FDA regulation of promotion of drugs: a legal primer
Drug Information Journal 1989; 23:625-633

HSL3664
Barsan WG.
Genentech, Inc, and symposium sponsorship
Annals of Emergency Medicine 1989; 18:908

HSL3666
Beasley R, Crane J, Burgess C, Pearce N, Jackson R.
Fenoterol and severe asthma mortality
New Zealand Medical Journal 1989; 102:294-295

HSL3667
Bell KD.
Regulating drug advertisements
Lancet 1989; 2:678

HSL3669
Bressler R.
Endorsement of “patient promise” program
Lancet 1989; 320:1355

HSL3670
Brickler EM.
Industrial marketing and medical ethics
New England Journal of Medicine 1989; 320:1690-1692

HSL3671
Burton JL.
Baldness and minoxidil advertising
Lancet 1989; 1:442-443

HSL3937
Finch KC.
To our readers: Publication guidelines for symposia
American Journal of Medicine 1989; 86:A25-A26

HSL3938
Fogel ML.
Survey of pharmaceutical promotion in a family medicine training program
Canadian Family Physician 1989; 35:1603-1605

HSL3939
Franaszek JB.
Genentech, Inc, and symposium sponsorship
Annals of Emergency Medicine 1989; 18:909

HSL3940
Franklin K.
The pharmaceutical tango
New Physician 1989; 38:(5):24-28

HSL3941
Freeman HL.
Supplement policy of the Journal
British Journal of Psychiatry 1989; 155:(6):6

HSL3942
Greenwood J.
Pharmaceutical representatives and the prescribing of drugs by family doctors
1989;

HSL3943
Hanpadungdhama A.
Trials of dipyrone in Thailand
Lancet 1989; 1:788

HSL3944
Hansson O
Inside Ciba-Geigy
Penang, Malaysia: International Organization of Consumers Unions 1989

HSL3945
Harvey K.
Drug advertising
Medical Journal of Australia 1989; 150:664-665

HSL3946
Harvey K.
What influences prescribing—scientific articles or promotional pressure?
Medical Journal of Australia 1989; 150:282-283

HSL3947
The effect of journal advertising on market shares of new prescriptions
Health Care Communications Inc 1989;

HSL3950
Hershfield NB.
The ethics of physician-pharmaceutical company relationships
Canadian Medical Association Journal 1989; 140:10

HSL3952
Holmes A, Wolfe S.
When a uniquely effective drug is teratogenic: the case of isotretinoin
New England Journal of Medicine 1989; 321:756

HSL3957
Kreling DH, Szvimbo JW.
Drug information sources used by physicians and pharmacists: a study of public hospitals in Zimbabwe
Journal of Social and Administrative Pharmacy 1989; 6:197-207

HSL3958
Kriegman AG.
Medical advice by celebrities
New England Journal of Medicine 1989; 320:742

HSL3959
Krome RL.
Genentech, Inc, and symposium sponsorship
Annals of Emergency Medicine 1989; 18:908-909

HSL3960
Kwok YS, Sylvan L.
Drug advertising
Medical Journal of Australia 1989; 150:664

HSL3963
Lexchin J.
Doctors and detailers: therapeutic education or pharmaceutical promotion?
Int J Health Serv 1989; 19:(4):663-79

HSL3964
Mansfield PR.
MaLAM calls for better drug information
Essential Drugs Monitor 1989; (8):9

HSL3965
Martin JH.
The ethics of physician-pharmaceutical company relationships
Canadian Medical Association Journal 1989; 140:10

HSL3967
McSherry J.
Medifacts tape: response
Canadian Family Physician 1989; 35:2219-2220

HSL3968
Mitchell AD.
Baldness and minoxidil
Lancet 1989; 1:910

HSL3969
Mitchell AA.
When a uniquely effective drug is teratogenic: the case of isotretinoin
New England Journal of Medicine 1989; 321:757-758

HSL3970
Montagne M.
Social exchange, values, and the marketing of pharmaceuticals
Journal of Pharmaceutical Marketing & Management 1989; 3:(3):45-55

HSL3971
Morris LA, Mazis MB, Brinberg D.
Risk disclosures in televised prescription drug advertising to consumers
Journal of Public Policy & Marketing 1989; 8:64-80

HSL3972
Neill JR.
A social history of psychotropic drug advertisements.
Soc Sci Med 1989; 28:(4):333-8

HSL3973
Rachlis M, Kushner C.
Second opinion: what’s wrong with Canada’s health-care system and how to fix it
1989;

HSL3974
Randall H.
Drug promotional problems
Medical Journal of Australia 1989; 150:743

HSL3976
Rosner F.
The ethics of accepting "free" gifts at conventions.
Cancer Invest 1989; 7:(3):295-6

HSL3981
Squires BP.
Continuing medical education: coming of age
Canadian Medical Association Journal 1989; 140:491

HSL3982
Sriwatanakul K.
Trials of dipyrone in Thailand
Lancet 1989; 1:788

HSL3985
Weir JH.
The arrhythmia consultation program
New England Journal of Medicine 1989; 321:908

HSL3986
Wilson JD.
Fenoterol and severe asthma mortality
New Zealand Medical Journal 1989; 102:295-296

HSL3987
Implementation of WHO’s revised drug strategy
1989;

HSL4001
Morton P, Williamson RR.
Treatment of herpes zoster [reply]
New Zealand Medical Journal 1989; 102:168

HSL4008
Roseman E.
Where the changing promotional mix is headed
Medical Marketing & Media 1989; 24:(6):10-13, 16, 18, 20

HSL4016
Antidiarrhoeals again under attack
Scrip 1989; (1457):29

HSL4018
Huston P.
Those promotional dinners: food for thought?
Medical Marketing & Media 1989; 24:(12):78, 80, 82, 84, 86, 88, 90

HSL4022
Schwartz H.
In defence of US pharma promotion
Scrip 1989; (1466):22-23

HSL4024
The basis of medical school cooperation with industry in the production of accredited continuing medical education
Journal of Continuing Education in the Health Professions 1989; 10:373-375

HSL9522
Mehta KK, Sorofman BA, Rowland CR.
Prescription drug advertising trends: a study of oral hypoglycemics.
Soc Sci Med 1989; 29:(7):853-7

HSL9524
Brown EG.
Patient information leaflets from pharmaceutical companies: survey of leaflets submitted to the Department of Health
Pharmaceutical Medicine 1989; 4:(2):123-129

HSL9531
Oliver D.
Research on competition and regulation in the prescription drug market
Journal of Research in Pharmaceutical Economics 1989; 1:(1):28-32

HSL9553
Eklund LH.
Drug cost containment-the case for generics: situation in Sweden
Journal of Social and Administrative Pharmacy 1989; 6:(1):6-8

HSL3555
Kiatboonsri P, Richter J.
Unethical trials of dipyrone in Thailand.
Lancet 1988 Dec 24-31; 2:(8626-8627):1491

HSL9566
Collier J.
The cases for and against prescribing generic drugs: generic prescribing benefits patients.
BMJ 1988 Dec 17; 297:(6663):1596,
http://www.pubmedcentral.nih.gov/articlerender.fcgi?tool=pubmed&pubmedid=3147089

HSL9567
Cruickshank JM.
The cases for and against prescribing generic drugs: don't take innovative research based pharmaceutical companies for granted.
BMJ 1988 Dec 17; 297:(6663):1597-8
http://www.pubmedcentral.nih.gov/articlerender.fcgi?tool=pubmed&pubmedid=3147090

HSL14717
Lexchin J.
Pushing pills: who's to blame for so much poor prescribing
The Globe and Mail 1988 Dec 13

HSL14718
McQuaig L.
MDs using Squibb drug in study receive computers for office use
The Globe and Mail 1988 Dec 13

HSL2063
Landgren FT, Harvey KJ, Mashford ML, Moulds RF, Guthrie B, Hemming M.
Changing antibiotic prescribing by educational marketing.
Med J Aust 1988 Dec 5-19; 149:(11-12):595-9

HSL9570
Denetclaw TH, Gomez D.
DEVELOPMENT OF A STUDENT/PHARMACIST SPEAKERS BUREAU
ASHP Midyear Clinical Meeting 1988 Dec; 23:

HSL9582
Guglielmo L, Ferrarese A, Castellani L, Carrara F.
Marketing, information and famotidine
Giornale Italiano di Farmacia Clinica 1988 Dec; 1:133-137

HSL3654
Brief submitted to the Pharmaceutical Inquiry of Ontario
1988 Nov 28; 10

HSL18909
Patel SJ
Freedom for traders, protection for manufacturers
Commonwealth Secretariat 1988 Nov 25

HSL3560
Lexchin J.
Antihypertensive drugs and advertising.
N Z Med J 1988 Nov 23; 101:(858):805

HSL3653
Postmarketing surveillance - how should doctors get involved?
Drug and Therapeutics Bulletin 1988 Nov 14; 26:(3):89-91

HSL3615
Thompson WG.
The ethics of physician-pharmaceutical company relationships.
CMAJ 1988 Nov 1; 139:(9):835-6

HSL3650
Re: the promotion of erythromycin with bromhexine
1988 Nov;

HSL3651
Direct-to-consumer advertising debated; APhA endorses some forms
American Pharmacy 1988 Nov; 28:(11):10-11

HSL3652
Danguilan MJ.
Drug commercials scored
Drug Monitor 1988 Nov; 3:(11):129-130

HSL9543
Direct-to-consumer advertising debated: APhA endorses some forms
American Pharmacy 1988 Nov; 28:10-11

HSL9556
McRoberts KM.
Direct to consumer: new route for ethical drug marketers
Pharmaceutical Executive 1988 Nov; 8:48, 51-52, 54, 56

HSL9565
Three drug manufacturers adopt JCPP stance on expiration dating
American Journal of Hospital Pharmacy 1988 Nov; 45:2272, 2274, 2276

HSL9559
Weston DR.
Canada might mandate ingredient disclosure on labels
Drug Topics 1988 Oct 17; 132:45

HSL3570
Musher DM.
Pharmaceutical company-sponsored symposia and medical ethics.
Am J Med 1988 Oct; 85:(4):596

HSL3647
Mann CC, Plummer ML.
The big headache
Atlantic Monthly 1988 Oct; 39-46, 48-49, 52-57

HSL3648
Mitchell JF, Pawlicki KS.
"Dispense as written" advertisements are demeaning to pharmacists.
Am J Hosp Pharm 1988 Oct; 45:(10):2073

HSL3649
Rosenthal E.
Madison Avenue medicine
Discover 1988 Oct; 9:(10):34-36

HSL9547
Kushner D.
When pharmacists choose: Part 2
American Druggist 1988 Oct; 198:82, 84, 86, 89-90, 95, 97-98,

HSL3578
Potter HP Jr.
Costs of drug advertising.
N Engl J Med 1988 Sep 22; 319:(12):798

HSL3645
Wells FO.
The code for promoting drugs.
BMJ 1988 Sep 10; 297:(6649):686-7

HSL3571
Nahata MC.
Drug package information in India.
Drug Intell Clin Pharm 1988 Sep; 22:(9):719

HSL3640
Editorial
Health Horizons 1988 Sep; (5):2
www.ifpma.rog/hhhs/welcome.htm

HSL3641
IFPMA code: the breach and the observence
Health Horizons 1988 Sep; (5):22-24
www.ifpma.rog/hhhs/welcome.htm

HSL3642
MaLAM letter follow up—Organon
MaLAM Newsletter 1988 Sep; 1

HSL3643
Re: the promotion of Rogin E
1988 Sep;

HSL9550
Lipman AG.
State of the pharmaceutical industry
Hospital Formulary 1988 Sep; 23:689

HSL3554
Kaufman JL.
Profligate medical marketing.
N Engl J Med 1988 Aug 25; 319:(8):522

HSL3558
Langman M.
The code for promoting drugs.
BMJ 1988 Aug 20-27; 297:(6647):499-500

HSL3610
Shaughnessy AF.
Drug promotion in a family medicine training center.
JAMA 1988 Aug 19; 260:(7):926

HSL3618
Vo-kyung S, Ok KIM.
Investigation of the violations of pharmaceutical regulations in advertisements of children’s medicines
1988 Aug 18-20;

HSL16718
Wolfe S
New Drugs Can Offer New Threat
USA Today 1988 Aug 5

HSL9577
Pearse WH.
Advertising of prescription drugs: 2
New England Journal of Medicine 1988 Aug 4; 319:314

HSL3613
Storrs FJ.
Drug samples? A conflict of interest
Arch Dermatol. 1988 Aug 01; 124:(8):1283-5

HSL3644
PMAC Code of Marketing Practices: a programme of industry self-regulation
PMAC Insight 1988 Aug; (21):1-5
www.canadapharma.org

HSL9564
Kaplan AH, Becker RH.
Sampling and the Prescription Drug Marketing Act of 1988
Pharmaceutical Executive 1988 Aug; 8:54, 56

Page 2 of 11 pages  < 1 2 3 4 >  Last ›

 

  Healthy Skepticism on RSS   Healthy Skepticism on Facebook   Healthy Skepticism on Twitter

Please
Click to Register

(read more)

then
Click to Log in
for free access to more features of this website.

Forgot your username or password?

You are invited to
apply for membership
of Healthy Skepticism,
if you support our aims.

Pay a subscription

Support our work with a donation

Buy Healthy Skepticism T Shirts


If there is something you don't like, please tell us. If you like our work, please tell others.







Cases of wilful misrepresentation are a rarity in medical advertising. For every advertisement in which nonexistent doctors are called on to testify or deliberately irrelevant references are bunched up in [fine print], you will find a hundred or more whose greatest offenses are unquestioning enthusiasm and the skill to communicate it.

The best defence the physician can muster against this kind of advertising is a healthy skepticism and a willingness, not always apparent in the past, to do his homework. He must cultivate a flair for spotting the logical loophole, the invalid clinical trial, the unreliable or meaningless testimonial, the unneeded improvement and the unlikely claim. Above all, he must develop greater resistance to the lure of the fashionable and the new.
- Pierre R. Garai (advertising executive) 1963